BlackRock Fund Advisors’s Heron Therapeutics HRTX Stock Holding History

BlackRock Fund Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$13.4M	Buy	1,019,962 +141,735	+16%	+$2.22M	﹤0.01%	2411
2016 Q3	$15.1M	Buy	878,227 +50,875	+6%	+$944K	﹤0.01%	2222
2016 Q2	$14.9M	Buy	827,352 +70,177	+9%	+$1.37M	﹤0.01%	2188
2016 Q1	$14.4M	Sell	757,175 -36,101	-5%	-$712K	﹤0.01%	2168
2015 Q4	$21.2M	Buy	793,276 +36,939	+5%	+$988K	﹤0.01%	2007
2015 Q3	$18.5M	Buy	756,337 +113,106	+18%	+$3.77M	﹤0.01%	2041
2015 Q2	$20M	Sell	643,231 -4,720	-0.7%	-$88.8K	﹤0.01%	2118
2015 Q1	$9.43M	Buy	647,951 +7,134	+1%	+$80.4K	﹤0.01%	2476
2014 Q4	$6.45M	Buy	640,817 +99,151	+18%	+$809K	﹤0.01%	2719
2014 Q3	$4.51M	Buy	541,666 +63,395	+13%	+$590K	﹤0.01%	2812
2014 Q2	$5.89M	Buy	+478,271	New	+$5.71M	﹤0.01%	2744

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

BlackRock Fund Advisors's HRTX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Heron Therapeutics (HRTX) stake by 16% in Q4 2016, buying an estimated $2.22M and bringing the position to 1,019,962 shares worth $13.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2411.

BlackRock Fund Advisors first reported a position in HRTX in Q2 2014 and has held it in 11 quarters since. The position peaked at $21.2M in Q4 2015. 99 funds tracked by Wall St. Rank hold HRTX as of Q4 2016.

BlackRock Fund Advisors held 1,019,962 shares of Heron Therapeutics worth $13.4M as of Q4 2016.
BlackRock Fund Advisors bought 141,735 Heron Therapeutics shares in Q4 2016, an estimated $2.22M.
Heron Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2411 holding.
BlackRock Fund Advisors first reported a position in Heron Therapeutics in Q2 2014 and has held it in 11 quarters since.
BlackRock Fund Advisors's Heron Therapeutics position peaked at $21.2M in Q4 2015.
99 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.